Patrick Vallance to join executive team at GSK

Has more than 20 years of experience of clinical medicine

Patrick Vallance will become senior vice president, Medicines Discovery and Development and a member of the Corporate Executive Team at GlaxoSmithKline on 1 July. Prior to joining GSK in 2006, Vallance was a clinical academic and led the Division of Medicine at University College London (UCL). He has more than 20 years of experience of clinical medicine and an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.

You may also like

Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: bepirovirsen for chronic hepatitis B

The hepatitis B virus causes both acute and chronic disease. Chronic hepatitis B can progress to complications including cirrhosis and liver cancer
Research & Development

Pfizer joins drug target identification consortium

Open Targets works pre-competitively, aiming to bridge the gap between pharma companies and not-for-profit research bodies
Research & Development

Sanofi and GSK announce positive preliminary COVID booster data

The companies' vaccine candidate delivered strong immune responses regardless of the primary vaccine received
Manufacturing

Manufacturing vaccines, digital twins and lessons learned: part II

Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual technology to improve the efficiency and agility of the production chain and expedite time-to-market
Research & Development

Sanofi and GSK COVID-19 vaccine shows promising Phase II results

The companies plan to initiate the Phase III, randomised, double-blind study with the 10 µg dose, in combination with GSK’s pandemic adjuvant, in the coming weeks
Subscribe now